POA Pharma Scandinavia

POA Pharma Scandinavia is a specialty pharmaceutical company headquartered in Copenhagen, Denmark, with a strong presence across the Nordic region and Germany. Acquired by Galen Limited (part of the Almac Group) in 2020, the company focuses on the distribution, marketing, and commercialization of proprietary, generic, and rare disease products. Its core expertise lies in medical nutrition for inborn metabolic diseases like Phenylketonuria (PKU), as well as acute care, ENT, and female healthcare. POA Pharma operates as a boutique healthcare firm, partnering with global manufacturers to bring specialized therapies to Northern European markets. The company manages a portfolio of over 75 products and provides comprehensive market access services, including regulatory support and sales infrastructure. Through its strategic expansion, POA Pharma continues to improve patient access to essential medicines and nutritional therapies throughout Scandinavia and beyond.